<DOC>
	<DOCNO>NCT01438151</DOCNO>
	<brief_summary>The purpose study improve investigator understand relationship Crohn 's disease blood level drug infliximab ( Remicade ) . The investigator want determine whether measure drug level helpful understanding patient respond treatment .</brief_summary>
	<brief_title>Understanding Relationship Between Infliximab Levels Clinical Response Remicade Crohn 's Disease</brief_title>
	<detailed_description>The efficacy infliximab maintain remission Crohn 's disease confirm randomize , control trial , however utility serum infliximab ATI titer less clearly described clinical practice set manage dose interval level . The primary objective study evaluate clinical responsiveness active ( HBI &gt; 10 ) Crohn 's disease infliximab relate serum infliximab level . Though assay infliximab level commercially available , current dosing practice rely assessment clinical data ( laboratory data , symptom , colonoscopy , etc ) . In order understand relationship , serum infliximab ATI titer collect course 8 ( approximately 1 year ) infusion . The result level retrospectively correlate patient 's clinical response treatment . The secondary objective identify predictor poor response infliximab evaluate efficacy dose escalation strategy patient classify primary secondary non-responders . Understanding association serum infliximab level disease response may useful objective tool optimize individualize dose amount frequency especially patient incomplete loss response therapy .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients active ( HBI &gt; 10 ) refractory inflammatory and/or perianal fistulizing Crohn 's disease prescribe infliximab standard care gastroenterologist . Pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Crohn 's disease</keyword>
	<keyword>Remicade</keyword>
	<keyword>infliximab</keyword>
</DOC>